Extremely dangerous self-amplifying (replicon) mRNA injections are actively being deployed worldwide

APR 2025 - U.S. FDA fast tracks Gates & BARDA- funded self-amplifying mRNA bird flu injection (Arcturus Therapeutics - ARCT - 2304)

FEB 2025 - EU approves COVID-19 saRNA injection (Arcturus Therapeutics - ARCT-154)

NOV 2024 - U.S. FDA authorizes trial for H5N1 bird flu saRNA injection (Arcturus Therapeutics - ARCT - 2304)

NOV 2023 - Japan fully approves COVID-19 saRNA injection (Arcturus Therapeutics - ARCT-154)

JUNE 2022 - India authorizes very first COVID-19 saRNA injection for human use (Gennova Biopharmaceuticals - GEMCOVAC-19)

There are currently at least 33 replicon mRNA injection candidates in development.

Kitonsa et al found that replicon saRNA injections induced severe blood abnormalities in 93% of trial participants.

https://www.mdpi.com/2076-393X/13/6/553

39 severe (Grade 3) lab abnormalities were reported after dose two among 42 healthy adults:

Thrombocytopenia (low platelets - increases risk of internal bleeding)

Lymphopenia & neutropenia (suppressed immune cells - raises infection and immune dysfunction risk)